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Abstract
The objective of this study was to determine if MTND2*LHON4917G (4917G), a specific non-synonymous polymorphism in
the mitochondrial genome previously associated with neurodegenerative phenotypes, is associated with increased risk for
age-related macular degeneration (AMD). A preliminary study of 393 individuals (293 cases and 100 controls) ascertained at
Vanderbilt revealed an increased occurrence of 4917G in cases compared to controls (15.4% vs.9.0%, p=0.11). Since there
was a significant age difference between cases and controls in this initial analysis, we extended the study by selecting
Caucasian pairs matched at the exact age at examination. From the 1547 individuals in the Vanderbilt/Duke AMD
population association study (including 157 in the preliminary study), we were able to match 560 (280 cases and 280
unaffected) on exact age at examination. This study population was genotyped for 4917G plus specific AMD-associated
nuclear genome polymorphisms in CFH, LOC387715 and ApoE. Following adjustment for the listed nuclear genome
polymorphisms, 4917G independently predicts the presence of AMD (OR=2.16, 95%CI 1.20–3.91, p=0.01). In conclusion, a
specific mitochondrial polymorphism previously implicated in other neurodegenerative phenotypes (4917G) appears to
convey risk for AMD independent of recently discovered nuclear DNA polymorphisms.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of
irreversible severe vision loss in Caucasians over the age of 50.[1]
Evidence from familial aggregation studies, twin studies, and
segregation analysis all point to a significant role for genetic
factors in the etiology of AMD.[2,3] Among common genetic
polymorphisms, the ApoE 2 allele appears to be associated with
increased susceptibility to AMD.[4] Recent genetic research has
focused primarily on the nuclear genome and resulted in
significant new associations, such as those in the Complement
Factor H gene (CFH) on Chromosome 1 and the HTRA1/
LOC387715 gene complex on Chromosome 10, with the AMD
phenotype.[5,6] However, variation in the mitochondrial genome
may also be important in the pathophysiology of age-related
diseases. This small, circular genome consists of only 16,569 base
pairs yet encodes for vitally important subunits in the mitochon-
drial electron transport chain as well as complete sets of tRNAs
and rRNAs. [7] Mitochondria are cytoplasmic organelles that play
a central role in cellular energy production, free radical
production, and apoptosis. Each of these processes has been
implicated in the pathogenesis of AMD. [8] Under normal
physiologic conditions, electrons leak from the mitochondrial
electron transport chain and reduce oxygen to superoxide anion,
initiating a cascade of free radicals, called reactive oxygen species
(ROS) that indiscriminately damage biological macromole-
cules.[9] These free radicals damage the mitochondria and thus
can compromise the production of ATP and trigger apoptosis.
Previous research has demonstrated that retinal pigment epithe-
lium is especially susceptible to damage by ROS. [10] Antioxi-
dants appear to ameliorate this effect.[10] Mitochondria are
especially susceptible to damage by ROS because the mitochon-
drial genome has limited reparative capacity. [7] In addition,
production of ROS, and hence susceptibility to AMD, may differ
depending on genetic variation within an individual’s mitochon-
drial genome.
Stable single nucleotide polymorphisms (SNPs) have emerged in
the mitochondrial genome over the past 150,000 years. [11]
Related combinations of these mtDNA polymorphisms define
haplogroups whose distribution differs between continents and
populations reflecting both human migration and acquired genetic
variation. [11]
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mitochondrial electron transport chains with different capacities
for energy production, free radical generation and apoptosis.
Variations in the mitochondrial genome have been associated
with neurodegenerative disorders, including Parkinson disease,
Alzheimer disease, Friedrich’s ataxia, and amytrophic lateral
sclerosis.[12] Mitochondrial haplogroup T has been associated
with male infertility due to asthenozoospermia with decreased
Complex I function.[13] In previous work we have associated
mitochondrial haplogroup T and specifically A4917G (4917G), a
non-synonymous mtDNA SNP closely linked to that haplogroup,
with nucleoside reverse transcriptase inhibitor (NRTI)-associated
peripheral neuropathy complicating therapy in HIV pa-
tients.[14,15] We hypothesized that 4917G may be related to
the neurodegenerative pathophysiology leading to the develop-
ment of AMD.
Materials and Methods
Study Population Ascertainment
AMD patients and unrelated controls were ascertained at both
Vanderbilt University Medical Center (VUMC) and Duke
University Medical Center (DUMC). The study protocol had
approval by the Institutional Review Boards at both institutions
and followed the tenets of the Declaration of Helsinki. Informed
consent was obtained from all participants.
The preliminary study group consisted of individuals ascer-
tained exclusively at Vanderbilt (N=393). Following the prelim-
inary study, the study population was expanded to include all
N=1547 individuals in the combined Vanderbilt/Duke AMD
study population. From this group, which included all individuals
in the preliminary study, we matched on the exact age (in years)
at the time of the examination in order to negate any con-
founding effect from the difference in age between cases and
controls. We were able to successfully match on exact age
for N=560 individuals (280 cases and 280 controls). Of these
560 individuals, 157 were in the preliminary study (83 cases and
74 controls). The age-matched group was an attempt at the
discovery of an association independent of other nuclear genetic
confounders and free of confounding from differences in age at
examination. In no way did this study represent a validation of the
initial finding since individuals are in both groups. The
preliminary data (N=393) is presented simply to report what
actually occurred.
Clinical Assessment
A standard protocol was used throughout ascertainment at
both locations. [16] A thorough medical history including ocular
and dietary information was obtained at the time of enrollment.
Additional information regarding specific risk factors for AMD
was obtained by a health and activities survey. All patients and
controls had complete ophthalmoscopic exams that included
both a slit-lamp examination and biomicroscopy with a 90-diopter
lens or fundus contact lens, and 20-diopter indirect ophthalmos-
copy of the peripheral retina. Fundus photographs (color 35-mm,
3 fields minimum) were obtained from a minimum of three fields
for all patients, including stereophotographs of the disk and
macula.[15] Vitreoretinal disease specialists (EAP and AA)
examined the fundus photographs of all participants and assigned
grades based on a modification of the AREDS grading system.
The overall grade for an individual was based on the grade of the
most severely affected eye. For this study, cases were defined as
individuals with grade 3 to grade 5 AMD. Controls had either
Grade 1 or Grade 2.
DNA Analysis
DNA was isolated from whole blood using PUREGENE
(Gentra Systems Inc., Minneapolis, MN, USA). Genotyping was
performed with the ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems Inc., Foster City, California, USA)
using the 59nuclease allelic discrimination Taqman assay. The
mtDNA 4917G snp was detected by using a MGB Eclipse Probe
because of a polymorphism at the position 4918 (Nanogen,
Bothell, WA). The 4917 forward primer was CAACTGCCTGC-
TA*TGATGGAT and the 4917 reverse primer was
GGCCTGCTTCTTCTCACATGACA (* represents a proprie-
tary nucleotide analog). The FAM probe for the wild type 4917
allele was TTACGA*TT*A*GT*GN*GG and the TET probe for
the 4917G allele was TTACGA*CTA*GT*GN*GG (with N and *
representing proprietary nucleotide analogs.) Genotypic data were
analyzed using ABI Sequence Detection System version 2.1
software and confirmed by visual inspection of the plots. The
genotyping for the specific CFH, LOC387715, and ApoE
polymorphisms were carried out using ABI assays that have been
described elsewhere. [5,6]
Statistical Analysis
Mitochondrial 4917G genotype frequencies were compared
between cases and controls using a x
2 test. The 4917G genotype
frequencies were calculated as the proportion of cases or controls
that carried A or G alleles. This polymorphism is generally
homoplasmic (only one allele is present in a given individual).
Tests for statistical significance were two-sided with an alpha level
of 0.05. Multivariable logistic regression was used to assess the
relationship between independent variables and the outcome.
Effect size for the association is measured as odds ratio (OR) with
95% confidence intervals. Statistical Analysis Software version 9.1
(SAS Institute, Cary, NC, USA) was used for all statistical analyses.
Results
The initial study population consisted of 393 individuals (293
cases and 100 controls) ascertained at Vanderbilt University
Medical Center. The clinical characteristics of these individuals
are presented in Table 1. All patients were Caucasian. The results
of the genotyping of these individuals are also incorporated into
Table 1. An increased occurrence of 4917G was observed in cases
compared to controls (15.4% vs 9.0%, p=0.11). The significant
difference in age between cases and controls (77.5 years67.5 vs.
67.8 years68.3, p,0.001) led to the use of an age-matching
strategy in the subsequent main study.
Table 1. Demographic, Clinical, and Genetic Characteristics of
the Initial Study Population.
Variable Cases Controls p-value
Number N=293 N=100
Age at Exam, mean6sd, years 77.567.5 67.868.3 ,0.001
Race, % Caucasian 100 100
Gender, % Female 63.8 58.0 0.300
rs1061170, CFH, %Allele C present 84.3 63.0 ,0.0001
rs10490924 LOC387715, %Allele T present 63.1 50.0 0.021
APOE, % ApoE2 allele 16.4 16.0 0.929
mtDNA 4917, % G allele 15.4 9.0 0.115
doi:10.1371/journal.pone.0002091.t001
MtDNA A4917G and AMD
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matched Caucasian pairs from the existing large AMD study
population ascertained at Vanderbilt and Duke University. The
age at exam of both groups was 70.0 years67.6. The univariate
analysis of both clinical and genotype data in this population is
presented in Table 2. This analysis revealed significant differences
between cases and controls for 3 nuclear polymorphisms- CFH
Y402H (rs1061170), LOC387715 (rs10490924), and ApoE, as well
as the mitochondrial polymorphism 4917G. For nuclear polymor-
phisms, the reported Odds Ratios (OR) reflects carriage of the risk
allele in either the homozygous or heterozygous state. In the case
of the mitochondrial polymorphism 4917G, virtually all individ-
uals (.99%) were homoplasmic for this polymorphism. The
multivariate regression analysis of this study population is
presented in Table 3. Following adjustment for gender and the
aforementioned three nuclear polymorphisms in this age-matched
Caucasian population, the mitochondrial 4917G polymorphism
remained an independent predictor of AMD (OR=2.16, 95%CI
1.20–3.91, p=0.01).
Discussion
In this study, we observed that 4917G, a non-synonymous
mitochondrial DNA polymorphism associated with mitochondrial
haplogroup T, appears to confer an increased risk for AMD. This
variation in the mitochondrial genome was an independent
predictor of AMD following multivariate adjustment for well-
known nuclear genetic factors. This observation should not be
surprising, since mitochondria are vitally important in free radical
production, apoptosis and cellular energy production. [17–19]
While this study provides epidemiologic evidence of relationship
between mtDNA 4917G and susceptibility to developing AMD,
the biological mechanism underlying this association remains to be
elucidated. The nonconservative amino acid change resulting from
the 4917G polymorphism in the ND2 gene may increase the rate
of electron leakage from the mitochondrial electron transport
chain. As a direct consequence, reactive oxygen species (ROS)
production may increase and result in damage to many important
biomolecules. [7,8] Increased mitochondrial free radical produc-
tion may therefore be an important shared feature in the
pathogenesis of a variety of neurodegenerative phenotypes. [12]
The mtDNA variations detected in late-onset diseases such as
AMD and Parkinson disease may persist in the population because
they do not have an effect sufficient to impair reproductive fitness.
Genetic factors other than 4917G are clearly important in
the development and progression of AMD. Our analysis of
other established genetic risk factors for AMD was consistent with
the published literature. However, 4917G remained an indepen-
dent predictor of AMD following adjustment for these known risk
factors. It is possible that the 4917G mtDNA polymorphism is in
linkage disequilibrium with more important causative polymor-
phisms. Of course, replication of these results in other populations
of suitable sample size and power will provide even more
convincing evidence for the role this mtDNA polymorphism plays
in AMD. Epistatic interactions between individual loci within the
mitochondrial genome as well as nuclear-mitochondrial gene
interactions, for instance perhaps involving LOC387715, will be
investigated further in larger studies. [20]
In summary, this study provides new evidence that variation in
the mitochondrial genome contributes to susceptibility to AMD.
The magnitude of the risk associated with the haplogroup T
suggests that it may be an important new risk factor for the
development of AMD. Future studies involving AMD will need to
take into account the distribution of 4917G in their study
populations. As we move forward with genome-wide association
studies of AMD that span the 6,000,000,000 base pairs of the
human diploid nuclear genome, it is worth noting again that
humans have two genomes. [21,22] Variations in the 16,569 base
pairs of the mitochondrial genome should not be overlooked in the
search to uncover new factors important in the development of
AMD and other diseases.
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Table 2. Univariate Analysis of MTND2*LHON4917G and
other factors involved in the development of AMD in N=280
Caucasian pairs matched on the exact Age at the Time of
Examination.
Variable Cases Controls p-value
Number N=280 N=280
Age at Exam, mean6sd, years 70.067.6 70.067.6
Race, % Caucasian 100 100
Gender, % Female 62.1 53.2 0.0328
rs1061170, CFH, %Allele C present 80.7 66.8 0.0002
rs10490924 LOC387715, %Allele T present 63.1 50.0 ,0.0001
APOE, % ApoE2 allele 16.4 16.0 0.0547
mtDNA 4917, % G allele 15.4 9.0 0.0140
doi:10.1371/journal.pone.0002091.t002
Table 3. Multivariate Analysis of MTND2*LHON4917G and
other factors involved in the development of AMD in N=280
Caucasian pairs matched on the exact Age at the Time of
Examination.
Variable Odds Ratio 95% CI p-value
Gender, % Female 1.41 0.99–2.00 0.0567
rs1061170, CFH, %Allele C present 1.97 1.32–2.94 0.0009
rs10490924 LOC387715, Allele T
present
1.95 1.38–2.77 0.0002
APOE, ApoE2 allele present 1.50 0.94–2.40 0.0807
mtDNA 4917, G allele present 2.16 1.20–3.91 0.0108
doi:10.1371/journal.pone.0002091.t003
MtDNA A4917G and AMD
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